Blog

The Bimek Spermatic Duct Valve: A preliminary clinical study

| 27. April 2016

The development of the Bimek spermatic duct valve has taken a crucial step forward; the ethics commission of a German university clinic has agreed to conduct a preliminary clinical study.

In the preliminary study a small group of volunteers will be selected to have the spermatic duct valves implanted. The valves will be inserted in an opened state. Volunteers will then be monitored for a period of about 6 months to see if sperm cells flow through the valves as intended. To keep track of this, the number and activity of sperm cells in the ejaculatory fluids of participants will be examined at regular intervals.

“We’re really happy about this decision,” adds Clemens Bimek, inventor of the Bimek spermatic duct valve. “We’ve been working towards this study for a very long time and see now that our efforts were regarded positively by the medical professionals and researchers involved. The fact that we’re at the starting line of a preliminary study has increased our confidence that the Bimek SLV will meet all expectations.”

Following its approval, the preliminary study is planned to begin in summer. The search for volunteers is, however, the smallest of our concerns. Since October 2015 about 5000 men from all over the world have, through a two-step process, already registered to volunteer for the implant surgery in context of the clinical studies.

“The immense feedback from the male community has really surprised us in the most positive of ways and so it really shouldn’t be a problem for the preliminary study to find enough suitable candidates, who will then be regarded as pioneers for male contraception,” explains Peter Schnückel, lead investor for the Bimek SLV. “At the moment, however, we’re still looking for investors who would like to be a part of the development and future economic success of this invention. We have also developed an attractive profit-sharing model, with which one can already acquire real Bimek shares starting from 75 000€. This is a chance to become a part of the contraceptive revolution, one shouldn’t let an opportunity like this slip by.”

More information for investors: https://bimek.com/invest-now/

Leave a Reply